PVPhilippe Vasseur

Philippe Vasseur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Vasseur has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Where to Biopsy to Detect Helicobacter pylori and How Many Biopsies Are Needed to Detect Antibiotic Resistance in a Human Stomach

    by Maxime Pichon, Cong Tri Tran, Gaëtan Motillon, Charlotte Debiais, Sylvain Gautier, Marie Aballea, Julie Cremniter, Philippe Vasseur, David Tougeron, Magali Garcia, et al.

    This study aims to determine the gastric distribution, density, and diversity of Helicobacter pylori infection. Subtotal resection of the stomachs of three H. pylori-infected and asymptomatic obese patients were collected after a sleeve gastrectomy. Distribution and density of H. pylori were determined using culture and RT-PCR on multiple gastric sites (88, 176, and 101 biopsies per patient). Diversity of H. pylori strains was studied using antibiotic susceptibility testing, random amplified polymorphism DNA (RAPD) typing and cagA gene detection on single-colony isolates (44, 96, and 49 isolates per patient). H. pylori was detected in nearly all analyzed sites (354/365 biopsies, 97%). Antral density was higher in one patient only. The three stomachs were almost exclusively infected by an antibiotic-susceptible strain. One clarithromycin-resistant isolate in one biopsy was detected in two stomachs (1/44 and 1/49 isolates), while in the third one, eight (8/96 isolates) metronidazole-resistant isolates were detected. DNA typing showed infection with cagA-negative strains for one patient, cagA-positive strains for a second patient and the third patient was infected with two different strains of distinct cagA genotypes. Infection with H. pylori is shown to spread to the whole surface of the stomach, but a possibility of minor sub-population of antibiotic-resistant clones, undetectable in routine practice.


  • Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study.

    by Cindy Neuzillet, Bertrand Brieau, Gregory Manuceau, Benoit Rousseau, Laetitia Dahan, Tarek Boussaha, Philippe Vasseur, David Tougeron, Thierry Lecomte, Romain Coriat, et al.

    4076 Background: There is no validated option beyond GEM-platinum standard 1st-line (L1) chemotherapy (CT) for ABTC. In ovarian and colon cancers, platinum rechallenge demonstrated benefit in patients who responded to a prior platinum-based CT and with a significant platinum-free interval. We aimed to assess the usefulness of platinum-based CT as 2nd (L2) or 3rd-line (L3) treatment in ABTC. Methods: Patients with ABTC who received platinum-based CT as L2 or L3 were identified from a national retrospective AGEO cohort of ATBC patients receiving L2 CT after failure of GEM-platinum L1 CT at 18 French institutions. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Results: Among 686 patients who received GEM-platinum L1 CT, 231 were given L2 CT; among them, 92 (39.8%) received a platinum-based CT as L2 (n = 70) or L3 (n = 25). Median age was 65 years (range: 25-81); 50 (54.3%) patients were men and 42 were women. The primary tumor was intrahepatic, extrahepatic and gallbladder carcinoma in 44/28/19 patients. L1 CT was GEMOX in 83 (90.2%) patients and GEMCIS in 9. At the time of platinum rechallenge, 82 (92.1%) patients had metastatic disease; ECOG PS was 0-1 in 73.6%; CA19.9 was > 400 IU/ml in 36.2%. Rechallenge regimens were 5FU-cisplatin (n = 53), FOLFOX/XELOX (n = 28), GEMOX/GEMCIS (n = 9), and carboplatin-based CT (n = 5). Overall, median L1 PFS (mPFS) was 7.2 months and median OS (mOS) from L1 was 17.4 months; mPFS and mOS from platinum rechallenge were 4.4 months (L2: 4.8; L3: 3.4) and 7.7 months (L2: 7.7; L3: 7.7), respectively. 82 patients were evaluable according to RECIST criteria; 12 (14.6%) had partial response and 40 stable disease (48.8%) (disease control rate [DCR] 63.4%). PS (0-1 vs 2-3) and CA19.9 (≤ vs > 400 IU/ml) were significantly associated with longer PFS (HR 2.41, p = 0.0016 and HR 1.88, p = 0.0350); PS, CA19.9, and reason for L1 discontinuation (toxicity/other vs progression) were significantly associated with longer OS (HR 2.17, p = 0.0019; HR 1.69, p = 0.0491; HR 1.77, p = 0.0122, respectively). Conclusions: Platinum rechallenge is an interesting option yielding a DCR over 60% in patients with ABTC.

  • High plasma levels of the pro-inflammatory cytokine IL-22 and the anti-inflammatory cytokines IL-10 and IL-1ra in acute pancreatitis

    by Philippe Vasseur, Iris Devaure, Jacques Sellier, Adriana Delwail, Carine Chagneau-Derrode, Florian Charier, David Tougeron, Jean-Pierre Tasu, Hanitriniaina Rabeony, Jean-Claude Lecron, et al.


  • Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study.

    by Bertrand Brieau, Laetitia Dahan, Yann De Rycke, Tarek Boussaha, Philippe Vasseur, David Tougeron, Thierry Lecomte, Romain Coriat, Jean Baptiste Bachet, Pierre Claudez, et al.

    4093 Background: First-line chemotherapy (CT1) with the combination of gemcitabine (gem) + platinum has become a new standard in advanced biliary tract cancer (ABTC) but data on second-line CT (CT2) are lacking. The aim of this study was to evaluate the efficacy and tolerability of CT2 in patients (pts) with ABTC who received gem-platinum in CT1. Methods: We retrospectively reviewed data of consecutive patients who received CT2 for ABTC after failure to gem-platinum in 17 French institutions from November 2002 to December 2013. Progression-free survival (PFS) and overall survival (OS) were estimated from the start of L2 CT using Kaplan Meier method. Cox models were applied for multivariate analyses. Results: Among 603 pts who were treated by gem-platinum in CT1, 196 pts (median age, 63 years, range: 28-82; male, 51.5 %) received a CT2. CT1 included gem + cisplatin (7%) or oxaliplatin (ox) (93%), with a median PFS of 9.7 months (mo) and an ORR of 31%. Characteristics at the beginning of CT2 were: metastatic disease, 94% ; 1-2 metastatic sites, 68%; ECOG PS 0-1, 68%. CT2 CT was 5FU-irinotecan (iri) (n=62), 5FU-ox (n=17), 5FU-cisplatin (n=37), 5FU/capecitabine (CAP) (n=39) or other various regimens (n=41). Among the 186 evaluable pts, there were 22 PR (12%) and 70 SD (38%). After a median follow-up of 26.4 months, median PFS and OS were 3.2 and 6.7 mo respectively. There was no significant difference between CT regimens in terms of PFS (5FU-iri, 2.6 mo; 5FU-ox/5FU-cisplatine, 4.0 mo; 5FU/CAP, 3.2 mo and others, 3.7 mo; p=0,27) and OS (6.0 mo, 6.3 mo, 5.6 mo and 9.7 mo respectively; p=0.27) In multivariate analysis, PS 2-3, bilirubine > 17 µmol/L and CA19.9 > 400 UI/mL were significantly associated with a shorter PFS while PS 2-3, CA19.9 > 400 UI/mL and non-response to CT1 with a shorter OS. A grade 3-4 toxicity was observed in 32% of pts (neutropenia, 33%; diarrhea, 17%) and a toxic death occurred in 1.4% of pts. Conclusions: CT2 is associated with a disease control in a half of pts with ABTC who received gem-platinum in CT1. Nevertheless, the short median PFS observed in this study should encourage the evaluation of new treatments in pts with good clinical conditions and an adequate biliary drainage.